Published in Cancer Weekly, April 13th, 2004
The compound did not demonstrate sufficient antitumor activity in the trial to satisfy Chiron's predetermined criteria to advance the program. The company had previously announced that it had concluded phase II development of tezacitabine in patients with colorectal cancer. No safety issues were identified in treatment with tezacitabine.
"Data from the phase II trial failed to meet Chiron's threshold for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.